Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mirabegron and solifenacin for prevention of catheter-related bladder discomfort after transurethral resection
ChiCTR1900028650Phase 4Recruiting
- Sponsor
- Capital Medical University
- Start
- Jan 2020
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of mirabegron and solifenacin in cystitis (3 arms), sponsored by Capital Medical University. Primary endpoints: Overactive Bladder Symptoms Score and Catheter-Related Bladder Discomfort. Started Jan 2020; status: recruiting.
02
Drugs
mirabegronsolifenacin
03
Conditions
cystitis
Beyond the preview
Go deeper on ChiCTR1900028650.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900028650.